Observational cohort study of rilpivirine (RPV) utilization in Europe.

ABSTRACT:

Introduction

Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce.

Methods

Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. A logistic regression model was used to compare participants' characteristics by treatment group. Kaplan-Meier analysis was used to estimate the cumulative risk of virological failure (VF, two consecutive values > 50 copies/mL).

Results

1,355 PLWH who started a RPV-based regimen (11% ART-naïve), as well as 333 initiating an EFV-containing regimen were included. Participants who sta

SUBMITTER: Cozzi-Lepri A 

PROVIDER: S-EPMC9357334 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature